CEM acquires key assets of Intavis Bioanalytical Instruments
CEM Corporation announced that it has entered into a definitive agreement to purchase the instrumentation lines of Intavis Bioanalytical Instruments AG, with headquarters in Cologne Germany. The acquisition allows CEM to strengthen its product offering in the Life Sciences for proteomics, in-situ hybridization and particularly in the field of peptide synthesis.
CEM
The Intavis instrumentation provides unique robotic synthesis technology that is very complementary to CEM’s line of microwave peptide synthesizers. In particular, this includes small scale highly-parallel formats for making peptides either on resins or membranes, which allow for direct screening. In contrast, CEM’s peptide synthesis technology provides extremely rapid and efficient peptide production at larger scales. With this acquisition, customers will now benefit from a complete portfolio of peptide synthesis technology available through CEM’s large global support network.
“We are very pleased to be acquiring the Intavis line of instruments and unique robotic technology. Strategically, it will expand CEM’s capabilities to fully support the development of peptide based therapeutics from early stage lead identification to preclinical and cGMP commercialization. In addition, this technology creates new bioscience sample preparation opportunities for CEM.” said Michael J. Collins, President and CEO of CEM.
Dr. Steffen Huettner, CEO of Intavis commented “We are proud to work together with CEM. This agreement enables a great future for the Intavis technologies and opens our company to focus on new developments”
During the transition, which is expected to last 4 months, Intavis will continue to sell and support their products. After the transition period, CEM will manufacture the Intavis instruments at their global headquarters in Matthews, NC. CEM will also assume full responsibility for sales, support, and service for all existing Intavis customers using its global support system.
Most read news
Organizations
Other news from the department business & finance
These products might interest you
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Enough is enough - Stem cell factor Nanog knows when to slow down
Structure of Supercritical Water Decoded
Blinking neurons give thoughts away
The science of fluoride flipping
3D images display plant organs down to the smallest detail - Intelligent software for a better understanding of plant tissue development
Molecular containers to capture the imagination
Cancer cells on the wrong path - How adaptations can make cancer treatment more difficult
Nanotechnology: Study shows urgent need for reference materials - Two new developments could bring decisive progress
First 3-D structure of DHHC enzymes reported
Third-highest oxidation state secures rhodium a place on the podium - Discovery is a real surprise